In contrast, emerging guidelines for patients with NSCLC and blood-based companion diagnostic testing for epidermal growth factor receptor (EGFR) mutations are currently used, with potential uses for advanced malignancies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.